Biocon Ltd vs Jagsonpal Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Biocon Ltd is ₹ 402.15 as of 12 May 15:30 . The P/E Ratio of Biocon Ltd changed from 66.3 on March 2021 to 40.4 on March 2025 . This represents a CAGR of -9.43% over 5 yearsThe P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Biocon Ltd changed from ₹ 49056 crore on March 2021 to ₹ 40964 crore on March 2025 . This represents a CAGR of -3.54% over 5 yearsThe Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Biocon Ltd for the Mar '26 is ₹ 4569 crore as compare to the Dec '25 revenue of ₹ 4290 crore. This represent the growth of 6.5% The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Biocon Ltd for the Mar '26 is ₹ 992.4 crore as compare to the Dec '25 ebitda of ₹ 657.4 crore. This represent the growth of 50.96% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Biocon Ltd changed from ₹ 861.8 crore to ₹ 198.6 crore over 8 quarters. This represents a CAGR of -52.00% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 9.85 % on March 2025 . This represents a CAGR of -38.69% over 4 yearsThe Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 years .

About Biocon Ltd

Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.
Also in the same year, the company had received US funding for proprietary technologies.

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

FAQs for the comparison of Biocon Ltd and Jagsonpal Pharmaceuticals Ltd

Which company has a larger market capitalization, Biocon Ltd or Jagsonpal Pharmaceuticals Ltd?

Market cap of Biocon Ltd is 65,184 Cr while Market cap of Jagsonpal Pharmaceuticals Ltd is 1,427 Cr

What are the key factors driving the stock performance of Biocon Ltd and Jagsonpal Pharmaceuticals Ltd?

The stock performance of Biocon Ltd and Jagsonpal Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Jagsonpal Pharmaceuticals Ltd?

As of May 12, 2026, the Biocon Ltd stock price is INR ₹402.15. On the other hand, Jagsonpal Pharmaceuticals Ltd stock price is INR ₹212.65.

How do dividend payouts of Biocon Ltd and Jagsonpal Pharmaceuticals Ltd compare?

To compare the dividend payouts of Biocon Ltd and Jagsonpal Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.